Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,276
datasets available to search
ShareScore release 0.9.0
Dataset results
1,276 results for “bleeding”
Ulcer Bleeding After Band Ligation of Esophageal Varices
ClinicalTrials.gov study NCT06082219. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Bleeding Prediction in Thrombocytopenia
ClinicalTrials.gov study NCT02306044. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Role of Frailty in Bleeding Risk Prediction in Acute Coronary Syndrome
ClinicalTrials.gov study NCT07158788. IPD Sharing: Not stated. Countries: 0. Publications: 0.
A Safety Trial to Compare Different Analgesics in Combination With Low Dose Aspirin to Study Their Bleeding Properties and Their Effects on the Stomach
ClinicalTrials.gov study NCT00261586. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Control of Bleeding on Nexplanon in Latinx Patients
ClinicalTrials.gov study NCT05116371. IPD Sharing: NO. Countries: 0. Publications: 0.
Different Methods of Tranexamic Acid Application in Controlling Peri Operative Bleeding in Gynecomastia Surgery
ClinicalTrials.gov study NCT06509256. IPD Sharing: YES. Countries: 0. Publications: 0.
IMPACT of KNOWLEDGE and SKILLS in MANAGEMENT of BLEEDING DURING PREGNANCY
ClinicalTrials.gov study NCT06832319. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Prevalence of Cesarean Section Niche in Women With Unexplained Abnormal Uterine Bleeding
ClinicalTrials.gov study NCT03130387. IPD Sharing: UNDECIDED. Countries: 0. Publications: 0.
Prognostic Value of Implementing VCE on Top in Constitutional VWD-patients With GI-bleeding
ClinicalTrials.gov study NCT04466878. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Bleeding Events and Oral Anticoagulant Treatment in Non-Valvular Atrial Fibrillation
ClinicalTrials.gov study NCT03002740. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Clinical and Economic Burden of Bleeding Events in Patients in the UK With Non-valvular Atrial Fibrillation Treated With Vitamin k Antagonists
ClinicalTrials.gov study NCT02661516. IPD Sharing: Not stated. Countries: 0. Publications: 0.
The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin
ClinicalTrials.gov study NCT01549418. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients
ClinicalTrials.gov study NCT03362281. IPD Sharing: Not stated. Countries: 0. Publications: 0.
TRanEXamic Acid to Decrease Heavy Menstrual Bleeding in Individuals Anticoagulated for Venous Thromboembolism Pilot Study
ClinicalTrials.gov study NCT06452342. IPD Sharing: NO. Countries: 0. Publications: 0.
Dataset related to article "One-Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus-Eluting Stents in High Bleeding Risk Patients"
<p>This record contains raw data related to article "One-Month Dual Antiplatelet Therapy After Bioresorbable Polymer Everolimus-Eluting Stents in High Bleeding Risk Patients"</p> <p>Abstract:</p> <p>Background It is unknown whether contemporary drug-eluting stents have a similar safety profile in high bleeding risk patients treated with 1-month dual antiplatelet therapy following percutaneous coronary interventions. Methods and Results We performed an interventional, prospective, multicenter, single-arm trial, powered for noninferiority with respect to an objective performance criterion to evaluate the safety of percutaneous coronary interventions with Synergy bioresorbable-polymer everolimus-eluting stent followed by 1-month dual antiplatelet therapy in patients with high bleeding risk. In case of need for an oral anticoagulant, patients received an oral anticoagulant in addition to a P2Y<sub>12</sub> inhibitor for 1 month, followed by an oral anticoagulant only. The primary end point was the composite of cardiac death, myocardial infarction, or definite or probable stent thrombosis at 1-year follow-up. The study was prematurely interrupted because of slow recruitment. From April 2017 to October 2019, 443 patients (age, 74.8±9.2 years; women, 29.1%) at 10 Italian centers were included. The 1-year primary outcome occurred in 4.82% (95% CI, 3.17%-7.31%) of patients, meeting the noninferiority compared with the predefined objective performance criterion of 9.4% and the noninferiority margin of 3.85% (<em>P<sub>noninferiority</sub></em><0.001) notwithstanding the lower-than-expected sample size. The rates of cardiac death, myocardial infarction, and definite or probable stent thrombosis were 1.88% (95% CI, 0.36%-2.50%), 3.42% (95% CI, 2.08%-5.62%), and 0.94% (95% CI, 0.35%-2.49%), respectively. Conclusions Among high bleeding risk patients undergoing percutaneous coronary interventions with the Synergy bioresorbable-polymer everolimus-eluting stent, a 1-month dual antiplatelet therapy regimen is safe, with low rates of ischemic and bleeding events. Registration URL: https://www.clinicaltrials.gov; Unique identifier: <a href="http://clinicaltrials.gov/show/NCT03112707">NCT03112707</a>.</p>
Are Viscoelastic Tests Clinically Useful to Identify Platelet-Dependent Bleeding in High-Risk Cardiac Surgery Patients?
<p>Baryshnikova E, Di Dedda U, Ranucci M. Are Viscoelastic Tests Clinically Useful to Identify Platelet-Dependent Bleeding in High-Risk Cardiac Surgery Patients? Anesth Analg. 2022 Dec 1;135(6):1198-1206. doi: 10.1213/ANE.0000000000006231. Epub 2022 Oct 13. PMID: 36227767.</p> <p>Abstract</p> <p><strong>Background: </strong>Postoperative use of platelet function testing to rule out microvascular bleeding due to platelet dysfunction after cardiac surgery still lacks strong reference data and reliable cutoff values, yielding a clinically adequate sensitivity and specificity. The present study aims to investigate the performance of two different point-of-care viscoelastic devices and platelet aggregometry in expressing surgery-dependent platelet dysfunction and anticipating postoperative major bleeding in a cohort of high-risk patients.</p> <p><strong>Methods: </strong>Prospective cohort study of 50 adult patients who were on antiplatelet drugs discontinued for no more than 7 days (clopidogrel and prasugrel) or 5 days (ticagrelor) undergoing cardiac surgery with cardiopulmonary bypass (CPB). Coagulation and platelet function testing, including QUANTRA, ROTEM, and Multiplate, were assessed preoperatively and postoperatively. Chest drain blood loss was measured in the first 12 postoperative hours. Perioperative bleeding was assessed using a modified version of the Universal Definition of Perioperative Bleeding (UDPB) in cardiac surgery, modified to not consider anemia-correcting packed red cells transfusions in the absence of bleeding >600 mL/12 h. Major bleeding was identified as UDPB class II or higher.</p> <p><strong>Results: </strong>Multiplate adenosine diphosphate (ADPtest) was significantly ( P = .001) reduced after CPB, whereas TRAPtest was not. The platelet component (PC) as extrapolated by ROTEM data (EXTEM MCF-FIBTEM MCF) was unchanged after CPB, while the A10 PC (PC at 10 minutes) was significantly ( P = .001) reduced. The QUANTRA platelet contribution to clot stiffness (PCS) was significantly ( P = .001) reduced, as well. At the ROC analysis for the predictive ability of the post-CPB platelet function testing, the best discrimination was obtained by the QUANTRA PCS, with an area under the curve (AUC) (95% confidence interval [CI]) of 0.80 (0.66-0.91), P = .001, followed by the ROTEM A10 PC with AUC (95% CI) of 0.75 (0.51-0.99), P = .004, and PC with AUC (95% CI) of 0.74 (0.50-0.99), P = .009. The Multiplate ADPtest had an AUC (95% CI) of 0.67 (0.42-0.91), and the TRAPtest had an AUC (95% CI) of 0.62 (0.37-0.86). The cutoff values identified were 13 hPa for the QUANTRA PCS, 40 mm for the ROTEM A10, and 48.5 mm for the ROTEM PC, with negative predictive values of 84%, 81%, and 86%, respectively, and positive predictive values of 55%, 53%, and 69%, respectively.</p> <p><strong>Conclusions: </strong>QUANTRA PCS, ROTEM A10 PC, and Multiplate ADPtest showed a significant decrease after CPB, whereas ROTEM PC and Multiplate TRAPtest did not. Major bleeding was predicted with a moderate to good discrimination by the post-CPB viscoelastic tests (PCS, PC, and A10 PC).</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.